adrenergic receptor Agonists
2 drugsAbout adrenergic receptor
Adrenergic receptors are a family of GPCRs activated by catecholamines like norepinephrine and epinephrine, regulating physiological processes. They are significant drug targets due to their involvement in various pathways.
While there is currently no genetic evidence directly linking adrenergic receptors to specific diseases, their role in diverse pathways makes them relevant across multiple therapeutic areas.
Two FDA-approved small molecule drugs, CLOZAPINE and VERSACLOZ, target adrenergic receptors, primarily for CNS indications. These drugs from Teva and Douglas highlight continued interest in adrenergic receptors.
Top adrenergic receptor Drugs
The competitive landscape includes two companies, Teva and Douglas Pharmaceuticals, with approved drugs.
Low market concentration suggests relatively low barriers to entry, but also potentially lower profitability.
adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities to develop novel modalities like antibodies or biologics to differentiate from existing therapies.
adrenergic receptor Clinical Trials 25 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 4 | 1 | 2 | 1 | 33% |
| Phase 4 | 19 | 11 | 2 | 6 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
adrenergic receptor Drug Approval Timeline (1996 - 2013)
The first drug was approved in 1996 (CLOZAPINE), and the most recent in 2013 (VERSACLOZ), spanning 18 years.
The approval timeline shows a slowing pace, indicating potential saturation or increased regulatory hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on adrenergic receptor. A trial counts if an approved drug acting on adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.